Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV

Jake A. Ruddy, Brian J. Boyarsky, William A. Werbel, Justin R. Bailey, Andrew H. Karaba, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Christine M. Durand

Research output: Contribution to journalArticlepeer-review

Abstract

In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.

Original languageEnglish (US)
Pages (from-to)1872-1874
Number of pages3
JournalAIDS (London, England)
Volume35
Issue number11
DOIs
StatePublished - Sep 1 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV'. Together they form a unique fingerprint.

Cite this